Effect of letrozole on shrinking the size of uterine fibroids in symptomatic patients of the reproductive age group
DOI:
https://doi.org/10.61581/mjsp.v6i3.340Keywords:
Aromatase Inhibitors, Fibroid , Leiomyoma, Letrozole, Uterine fibroidsAbstract
Objective: To compare the mean fibroid size (cm) before and after treatment with letrozole and the frequency of symptom improvement in symptomatic patients of the reproductive age group.
Methodology: Quasi-experimental study was conducted between November 1st, 2024, and April 30th, 2025, at the Obstetrics and Gynaecology Department of Nishtar Hospital in Multan. Thirty women aged 25-45 who presented to the outpatient department were enrolled in this study. Throughout the trial, married women were encouraged to use barrier methods of contraception. Symptoms were graded according to the operational definition. Every woman took 5mg of the tablet Letrozole daily for three months. The myoma size before and after treatment, and the improvement of symptoms, were recorded.
Results: The mean age of the study population was 34.70 ± 5.31 years. Most patients were married (76.7%, n=23), had 0–2 children (66.7%, n=20), and were non-obese (73.3%, n=22). Leiomyomas were primarily single in 63.3% (n=19) patients, with a mean size of 4.63 ± 1.22 cm, and 60.0% (n=18) exceeded 5 cm. Letrozole therapy significantly reduced uterine fibroid size from 5.37 ± 0.88 cm (pre-treatment) to 4.64 ± 0.70 cm (post-treatment), with a mean reduction of 0.73 cm (p=0.003). Among 30 patients, 66.7% (n=20) reported symptom improvement after letrozole therapy.
Conclusion: Reduced uterus-leiomyoma size, improved control of related symptoms, and fewer adverse effects were observed after treatment with Letrozole.
Key Words: Aromatase Inhibitors; Fibroid; Leiomyoma; Letrozole; Uterine fibroids;
Downloads
References
1. Xess S, Sahu J. A study to correlate association between vitamin D with fibroid and its supplementation in the progression of the disease. Int J Reprod Contracept Obstet Gynecol. 2020;9(4):1477. Available from: http://dx.doi.org/10.18203/2320-1770.ijrcog20201208
2. Leyland N, Leonardi M, Murji A, Singh SS, Al-Hendy A, Bradley L. A call-to-action for clinicians to implement evidence-based best practices when caring for women with uterine fibroids. Reprod Sci. 2022;29(4):1188–96. Available from: http://dx.doi.org/10.1007/s43032-022-00877-3
3. Liao S, Wang X, Fu N, Huang Y. High-intensity focussed ultrasound and hysteroscopy endo-operative system cold device procedures for treating> 4cm diameter FIGO Type 2 uterine myoma and ensuring successful pregnancy. The European Journal of Contraception & Reproductive Health Care. 2023;28:223–6.
4. Peng X, Chen H, Tan X, Wang X, Liu J. Possible new application of high-intensity focused ultrasound: degradation of uterine myoma classification. Int J Hyperthermia. 2024;41(1):2440545. Available from: http://dx.doi.org/10.1080/02656736.2024.2440545
5. Angioni S, D’Alterio MN, Daniilidis A. Highlights on medical treatment of uterine fibroids. Curr Pharm Des. 2021;27(36):3821–32. Available from: http://dx.doi.org/10.2174/1381612826666210101152820
6. Kirschen GW, AlAshqar A, Miyashita-Ishiwata M, Reschke L, El Sabeh M, Borahay MA. Vascular biology of uterine fibroids: connecting fibroids and vascular disorders. J Reprod Fertil. 2021;162(2):R1–18. Available from: http://dx.doi.org/10.1530/REP-21-0087
7. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149(1):3–9. Available from: http://dx.doi.org/10.1002/ijgo.13102
8. Mukherjee AG, Wanjari UR, Nagarajan D, K K V, V A, P JP, et al. Letrozole: Pharmacology, toxicity and potential therapeutic effects. Life Sci. 2022;310(121074):121074. Available from: http://dx.doi.org/10.1016/j.lfs.2022.121074
9. Prakash R, Pandey S, Chawla I. Effects of letrozole on patients with symptomatic leiomyoma in the reproductive age women. Int J Reprod Contracept Obstet Gynecol. 2017;6(5):2026. Available from: http://dx.doi.org/10.18203/2320-1770.ijrcog20171970
10. Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):329–32. Available from: http://dx.doi.org/10.1016/j.ejogrb.2013.09.010
11. Mangal S. Current knowledge on the use of letrozole in ovarian stimulation. Int J Infertil Fetal Med. 2021;11(2):48–53. Available from: http://dx.doi.org/10.5005/jp-journals-10016-1205
12. Ciebiera M, Madueke-Laveaux OS, Feduniw S, Ulin M, Spaczyński R, Zgliczyńska M, et al. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids-current roles and future perspectives. Expert Opinion on Pharmacotherapy. 2023;24(16):1799–809.
13. Giannopoulou EZ, Brandt S, Zorn S, Denzer C, von Schnurbein J, Fukami M, et al. Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome. Front Endocrinol (Lausanne). 2024;15:1487884. Available from: http://dx.doi.org/10.3389/fendo.2024.1487884
14. Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, et al. New insights into hormonal therapies in uterine sarcomas. Cancers (Basel). 2022;14(4):921. Available from: http://dx.doi.org/10.3390/cancers14040921
15. Liang AL, Katebi Kashi P, Hopkins M, Beavis A, Gaillard S, Shih IM, et al. Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report. Gynecol Oncol Rep. 2021;38(100877):100877. Available from: http://dx.doi.org/10.1016/j.gore.2021.100877
16. Clemenza S, Vannuccini S, Ruotolo A, Capezzuoli T, Petraglia F. Advances in targeting estrogen synthesis and receptors in patients with endometriosis. Expert Opin Investig Drugs. 2022;31(11):1227–38. Available from: http://dx.doi.org/10.1080/13543784.2022.215232.
17. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192–8. Available from: http://dx.doi.org/10.1016/j.fertnstert.2008.09.064
18. Hussain U, Nazar N, Essa M, Shoiab U, Imran M, Waheed F, et al. Comparison of gonadotropin releasing hormone agonists (GNRHA) vs aromatase inhibitors on volume of uterine leiomyomas in premenopausal women. JCP. 2023;7(2):63–8.
19. Chen WC, Hsu CC, Huang HJ, Cheng WJ, Chang TC, Chou HH. Letrozole as premedication of high intensity focused ultrasound treatment of uterine fibroids: A retrospective observation study. Front Med (Lausanne). 2022;9:1069654. Available from: http://dx.doi.org/10.3389/fmed.2022.1069654
20. Cook H, Ezzati M, Segars JH, McCarthy K. The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol. 2010;62(3):225–36.
21. Vlahos NF, Theodoridis TD, Partsinevelos GA. Myomas and adenomyosis: Impact on reproductive outcome. Biomed Res Int. 2017;2017:5926470. Available from: http://dx.doi.org/10.1155/2017/5926470.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Amara Malik, Saima Ashraf, Moiz Hassan Azdee
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
